Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-18
2011-01-18
Krass, Frederick (Department: 1612)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S303000, C514S341000, C514S352000, C514S355000, C514S407000
Reexamination Certificate
active
07872015
ABSTRACT:
The invention relates to the field of biology, genetics and medicine. In particular, the invention relates to novel methods for the detection, characterization and/or treatment (or management) of neurodegenerative pathologies. The invention also relates to methods for the identification or screening of compounds active in the aforementioned pathologies. The invention further relates to the compounds, genes, cells, plasmids or compositions which are used to carry out said methods. In particular, the invention is based on the identification of the role of phosphodiesterase 4B, the peripheral benzodiazepine receptor (PBR) and GABA receptors of the type GABA(A) in neurodegenerative pathologies and describes the use of same as therapeutic, diagnostic or experimental markers or targets for said disorders.
REFERENCES:
patent: 4904472 (1990-02-01), Belardinelli et al.
patent: 6083483 (2000-07-01), Stief et al.
patent: 6326201 (2001-12-01), Fung et al.
patent: 2002/0119923 (2002-08-01), Benowitz
patent: 2002/0132826 (2002-09-01), Levin et al.
patent: 2002/0177599 (2002-11-01), Allerton et al.
patent: 0 583 821 (1994-02-01), None
patent: 1 403 270 (2004-03-01), None
patent: 95/28926 (1995-11-01), None
patent: 98/53856 (1998-12-01), None
patent: 00/15222 (2000-03-01), None
patent: 01/49321 (2001-07-01), None
patent: WO01/049321 (2001-07-01), None
patent: 01/58469 (2001-08-01), None
patent: 01/81348 (2001-11-01), None
patent: 02/051502 (2002-07-01), None
patent: 02/098878 (2002-12-01), None
patent: 03/016563 (2003-02-01), None
patent: 03/045949 (2003-06-01), None
patent: 03/099278 (2003-12-01), None
patent: 2004/011464 (2004-02-01), None
patent: 2004/024085 (2004-03-01), None
Cavalia et al (Current Medicinal Chemistry 2 (1995) 561-572).
Amabati et al (Survey Of Ophthalmology vol. 48, No. 3 (2003) pp. 257-293).
International Search Report for PCT/FR2004/000366 dated Jan. 14, 2005.
Database WPI Week 200315, Dec. 19, 2002, Derwent Publications Ltd., AN: 2003-156939, XP002294573; Aotsuka et al. & WO 02/100859.
Database WPI Week 199641, Aug. 6, 1996, Derwent Publications Ltd., AN: 1996-408420, XP002266210; JP19950012463, Yoshitomi Pharm Ind KK.
Beatty S et al. (Surv Ophthalmol. Sep.-Oct. 2000;45(2):115-34 “The role of oxidative stress in the pathogenesis of age-related macular degeneration.” (Abstract).
Hubschman JP et al, Clin Ophthalmol. 2009;3:167-74 “Age-related macular degeneration: current treatments”.
Marcade et al, J Neurochem. Jul. 2008;106(1):392-404 “Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing” (Abstract).
Desire Laurent
Resink Annelies
Rouquette Magali
Schweighoffer Fabien
Exonhit Therapeutics SA
Krass Frederick
Nixon & Vanderhye P.C.
Packard Benjamin
LandOfFree
Methods involving PDE4, compositions, and the screening... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods involving PDE4, compositions, and the screening..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods involving PDE4, compositions, and the screening... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2711625